| 前收盘价格 | 6.27 |
| 收盘价格 | 6.31 |
| 成交量 | 724,098 |
| 平均成交量 (3个月) | 924,677 |
| 市值 | 562,361,536 |
| 价格/销量 (P/S) | 2.35 |
| 股市价格/股市净资产 (P/B) | 1.63 |
| 52周波幅 | |
| 利润日期 | 26 Feb 2025 - 3 Mar 2025 |
| 营业毛利率 | -104.52% |
| 营业利益率 (TTM) | -55.94% |
| 稀释每股收益 (EPS TTM) | -1.73 |
| 季度收入增长率 (YOY) | 40.90% |
| 总债务/股东权益 (D/E MRQ) | 27.08% |
| 流动比率 (MRQ) | 4.68 |
| 营业现金流 (OCF TTM) | -50.77 M |
| 杠杆自由现金流 (LFCF TTM) | -21.16 M |
| 资产报酬率 (ROA TTM) | -18.78% |
| 股东权益报酬率 (ROE TTM) | -57.52% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 混合的 | 混合的 | |
| 股票 | Personalis, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.8
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.75 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 19.30% |
| 机构持股比例 | 53.15% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Blue Water Life Science Advisors, Lp | 30 Sep 2024 | 1,000,000 |
| State Of Michigan Retirement System | 30 Sep 2024 | 493,798 |
| Wellington Shields Capital Management, Llc | 30 Sep 2024 | 432,181 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 11.00 (HC Wainwright & Co., 65.66%) | 购买 |
| 中 | 9.13 (37.50%) | |
| 低 | 7.25 (Needham, 9.19%) | 购买 |
| 平均值 | 9.13 (37.50%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 5.75 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Dec 2024 | 11.00 (65.66%) | 购买 | 5.75 |
| Needham | 20 Dec 2024 | 7.25 (9.19%) | 购买 | 5.75 |
| 07 Nov 2024 | 7.25 (9.19%) | 购买 | 4.32 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 19 Dec 2024 | 公告 | Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna |
| 16 Dec 2024 | 公告 | Personalis and Tempus Expand Collaboration to Biopharma |
| 20 Nov 2024 | 公告 | Personalis to Participate at Upcoming Investor Conferences |
| 06 Nov 2024 | 公告 | Personalis Reports Third Quarter 2024 Financial Results |
| 05 Nov 2024 | 公告 | Personalis to Present at the Stifel 2024 Healthcare Conference |
| 23 Oct 2024 | 公告 | Personalis to Announce Third Quarter 2024 Financial Results |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合